Dominari Holdings Files $2 Billion Shelf to Support Strategic Expansion

PR Newswire


NEW YORK
, Aug. 28, 2025 /PRNewswire/ — Dominari Holdings Inc. (Nasdaq: DOMH) today announced the filing of its shelf registration statement (the “Shelf Registration”) on Form S-3 with the U.S. Securities and Exchange Commission (the “SEC”). If the Shelf Registration is declared effective, it will permit the Company to offer and sell, from time to time in one or more offerings, up to $2 Billion worth of shares of common stock, preferred stock, or any combination thereof (the “securities”). Although we have no current intention to use the Shelf Registration Statement, depending on numerous factors, including the development of current and future business initiatives, we intend to use the net proceeds from any sales under the Shelf Registration Statement for working capital, capital expenditures, funding potential acquisitions and other business opportunities, including but not limited to, the establishment of a cryptocurrency treasury strategy.

A registration statement related to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement has become effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Any offering of the securities covered under the shelf registration statement, once it has become effective, will be made solely by means of a prospectus and an accompanying prospectus supplement relating to that offering, nor shall there be any sale of such securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any such state.

For additional information about Dominari Holdings Inc., please visit: https://www.dominariholdings.com/

About Dominari Holdings Inc.

The Company is a holding company that, through its various subsidiaries, is currently engaged in wealth management, investment banking, sales and trading and asset management. In addition to capital investment, Dominari Holdings provides management support to the executive teams of its subsidiaries, helping them to operate efficiently and reduce cost under a streamlined infrastructure. In addition to organic growth, the Company seeks opportunities outside of its current business to enhance shareholder value, including in the AI and Data Center sectors.

Dominari Securities LLC’s Mission Statement:

Dominari Securities LLC, a principal subsidiary of Dominari Holdings Inc., is a dynamic, forward-thinking financial services company that seeks to create wealth for all stakeholders by capitalizing on emerging trends in the financial services sector and identifying early-stage future opportunities that are expected to generate a high rate of return for investors.

Securities Brokerage and Registered Investment Adviser Services are offered through Dominari Securities LLC, a Member of FINRA, MSRB and SIPC. Securities brokerage, investment adviser and other non-bank deposit investments are not FDIC insured and may lose some or all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA’s BrokerCheck site at https://brokercheck.finra.org. Information for Dominari Securities LLC and its registered investment professionals as well as its SEC Form CRS may also be found on FINRA’s BrokerCheck site.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, which include but are not limited to the Risk Factors set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 relating to its business. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contacts:
Dominari Holdings Inc.

https://www.dominariholdings.com/

Investor Relations
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: [email protected]
www.haydenir.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/dominari-holdings-files-2-billion-shelf-to-support-strategic-expansion-302540505.html

SOURCE Dominari Holdings Inc.

CGI completes acquisition of Apside, a France-based digital and engineering services leader

PR Newswire

Stock Market Symbols

GIB.A (TSX)

GIB (NYSE)


cgi.com/newsroom


PARIS
, Aug. 28, 2025 /PRNewswire/ – CGI (TSX: GIB.A) (NYSE: GIB), one of the largest independent IT and business consulting services firms in the world, has completed its previously announced acquisition of Apside, a leading provider of digital and engineering services.

Present in France, Belgium, Canada, Morocco, Portugal and Switzerland, Apside is recognized for its in-depth industry knowledge in manufacturing, finance, insurance and the public sector, as well as its technology expertise in areas such as data, AI, cloud and cybersecurity.

With this acquisition, CGI further consolidates its presence in France as well as other European countries and Morocco, and strengthens its capabilities, particularly in manufacturing and financial services.

More than 2,500 professionals have joined CGI through this acquisition, including nearly 2,200 in France.

“We are delighted to welcome Apside’s talented team to CGI. Our companies share a culture and common values focused on innovation, responsibility, commitment and putting our employees at the heart of everything we do. By combining our strengths, we are enriching our technology offering and strengthening our ability to support our clients in their most complex transformations,” said Caroline de Grandmaison, President of CGI’s France operations.

About CGI

Founded in 1976, CGI is among the largest independent IT and business consulting services firms in the world. With 93,000 consultants and professionals across the globe, CGI delivers an end-to-end portfolio of capabilities, from strategic IT and business consulting to systems integration, managed IT and business process services and intellectual property solutions. CGI works with clients through a local relationship model complemented by a global delivery network that helps clients digitally transform their organizations and accelerate results. CGI Fiscal 2024 reported revenue is CA$14.68 billion and CGI shares are listed on the TSX (GIB.A) and the NYSE (GIB). Learn more at cgi.com

Cision View original content:https://www.prnewswire.com/news-releases/cgi-completes-acquisition-of-apside-a-france-based-digital-and-engineering-services-leader-302541030.html

SOURCE CGI Inc.

Leading Silicon Coating Manufacturer to Sell Fully Equipped Pressure-Sensitive Release Liner Manufacturing Plant on AllSurplus Marketplace

BETHESDA, Md., Aug. 28, 2025 (GLOBE NEWSWIRE) — Liquidity Services (NASDAQ: LQDT), a leading global commerce company powering the circular economy, today announced the sale of a fully equipped pressure-sensitive release liner manufacturing plant located in Eden, North Carolina. The sale is being conducted in conjunction with Perry Equipment Company and Mark One Machinery via a make offer format on AllSurplus, the leading online marketplace for surplus business assets.

“This sale represents a unique opportunity for manufacturers in the label, tape, medical, and industrial sectors to acquire a turnkey coating and converting operation,” said Chris Register, VP, Corporate Services at Liquidity Services. “With major systems installed as recently as 2023, the facility offers modern capabilities and immediate production potential.”

The offering includes extrusion and gravure coating lines, slitter rewinders, flexographic printing, robotic roll handling and wrapping systems, mobile material-handling equipment, core cutters, storage silos, air compressors, and a well-equipped maintenance shop. The plant remains installed and in good condition, designed for the production of silicone-coated paper and film liners.

Please visit AllSurplus.com to browse the event or to place a bid. Virtual tours of both plants can be accessed here: Plant 1, Plant 2.

About AllSurplus

AllSurplus is the world’s leading online marketplace for surplus business assets, ranging from heavy equipment to transportation and industrial machinery. AllSurplus is the smartest, fastest way to sell inventory and equipment as sellers can directly launch and manage their listings in just days with more control and lower fees than traditional auction solutions. AllSurplus is powered by one of the most experienced and trusted companies in the surplus industry: Liquidity Services (NASDAQ:LQDT), which has supported millions of customers across the globe. AllSurplus buyers have direct access to all the surplus assets across Liquidity Services’ network of marketplaces in one centralized location.

About Perry Equipment Company

Perry Equipment Company is a global supplier of used process equipment, serving the chemical, pharmaceutical, food, plastics, paper, and converting industries. With decades of experience, Perry offers a wide range of machinery and services to help businesses maximize value and efficiency in their operations.

About Mark One Machinery

Mark One Machinery specializes in the sale of used converting and extrusion equipment for the flexible packaging industry. With a commitment to quality and customer service, Mark One provides tailored solutions to meet the unique needs of manufacturers worldwide.



Contact:
Liquidity Services, Inc.
Public Relations
[email protected]

GlobalFoundries Announces Availability of 22FDX+ RRAM Technology for Wireless Connectivity and AI Applications

Latest technology in GF’s embedded memory portfolio is now available for prototyping

SANTA CLARA, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) — Today at its annual Technology Summit in California, GlobalFoundries (Nasdaq: GFS)(GF) announced the availability of its 22FDX+ with Resistive RAM (RRAM) technology, marking a significant advancement in the company’s portfolio of embedded non-volatile memory (eNVM) solutions. The new RRAM technology, when combined with the high-performance, ultra-low power 22FDX® platform, delivers secure, low-latency, high-density embedded memory for code storage for wireless microcontrollers and AI IoT applications.

Designed with industry-proven OxRAM technology, GF’s embedded RRAM offers cost-effective memory with low power read/write, high endurance and excellent retention. On-chip integration with GF’s enhanced 22FDX platform delivers improved data retention, reliability, security and power efficiency, creating compact and versatile system-on-chip (SoC) solutions for intelligent, connected devices.

RRAM’s high density and scalability are ideal for AI-enabled, IoT devices that rely on high-performance intelligence at the edge, such as sensors, wearables and industrial systems. 22FDX+ RRAM also enables weight storage for neural networks, enabling more effective and complex networks.

“We are pleased to add 22FDX+ RRAM to GF’s growing portfolio of differentiated technologies with the advanced features needed for power-efficient, connected intelligence at the edge,” said Ed Kaste, senior vice president of GF’s ultra-low power CMOS product line. “Our latest solution offers a compelling combination of density, performance and power efficiency, making it well-suited to tackle the challenges of next-generation, AI-enabled and connected devices.”

“GlobalFoundries is an important partner for Nordic Semiconductor as we push the boundaries of ultra-low power wireless solutions for the next generation of connected products and AI-enabled devices,” said Oyvind Strom, EVP Short-Range at Nordic Semiconductor. “We welcome GF’s introduction of embedded RRAM as a significant advancement that enables secure, scalable, and power-efficient edge intelligence. This kind of innovation – delivered through a resilient global supply chain – is essential to meeting growing demands for performance, reliability, and sustainability in connected systems.”

A macro preliminary design kit for 22FDX+ RRAM is available through GF’s self-service GF Connect portal to help jumpstart the design process. Volume production is slated for 2026, driven by several key customer engagements. Future generations of embedded RRAM technology and deployments to other platforms are in development.

About GF

GlobalFoundries (GF) is a leading manufacturer of essential semiconductors the world relies on to live, work and connect. We innovate and partner with customers to deliver more power-efficient, high-performance products for the automotive, smart mobile devices, internet of things, communications infrastructure and other high-growth markets. With our global manufacturing footprint spanning the U.S., Europe, and Asia, GF is a trusted and reliable source for customers around the world. Every day, our talented global team delivers results with an unyielding focus on security, longevity, and sustainability. For more information, visit www.gf.com.

Forward-looking information

This news release may contain forward-looking statements, which involve risks and uncertainties. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. GF undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

Media Contact:

Stephanie Gonzalez
[email protected]



DEADLINE TOMORROW: Berger Montague Advises Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) Investors to Inquire About a Securities Fraud Class Action by August 29, 2025

PR Newswire


PHILADELPHIA
, Aug. 28, 2025 /PRNewswire/ — Berger Montague, a national securities litigation law firm announces it is investigating potential securities fraud claims involving Petco Health and Wellness Company, Inc. (“Petco” or the “Company”) (NASDAQ: WOOF), following the recent filing of a federal securities class action lawsuit.

The complaint alleges that Petco made false and misleading statements about the sustainability of its pandemic-driven growth and premium product strategy. These alleged misstatements contributed to significant declines in Petco’s stock price, including a drop of over 20% on August 24, 2023, and further substantial losses following subsequent financial disclosures and executive departures during the Class Period from January 14, 2021 through June 5, 2025.

The lawsuit also highlights Petco’s efforts to adjust its product mix by adding lower-cost pet food options, which contrasted with prior public statements. This shift, along with multiple leadership changes and continued downward revisions to earnings guidance, underscored the severity of the Company’s challenges and negatively impacted investor confidence.

Investors who purchased or acquired Petco securities during the Class Period may, no later than August 29, 2025, seek to be appointed as a lead plaintiff representative of the class.


If you are a Petco investor and would like to learn more about this action,




CLICK HERE


 or please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267)764-4865.

About Berger Montague

Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago and Toronto, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

For more information or to discuss your rights, please contact:

Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
[email protected]

Caitlin Adorni
Berger Montague
(267) 764-4865
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/deadline-tomorrow-berger-montague-advises-petco-health-and-wellness-company-inc-nasdaq-woof-investors-to-inquire-about-a-securities-fraud-class-action-by-august-29-2025-302540564.html

SOURCE Berger Montague

VEON and Kyivstar to Host Investor Meeting on August 28, 2025

New York, August 28, 2025 – VEON Ltd. (Nasdaq: VEON), a global digital operator and Kyivstar Group Ltd. (Nasdaq: KYIV; KYIVW), a leading telecommunications and digital operator in Ukraine (“Kyivstar”), announced today that Kyivstar will host an investor meeting on Thursday, August 28, 2025, from 10:00 AM to 11:30 AM Eastern Time.

The meeting will provide an update on Kyivstar’s strategic initiatives, financial performance, and market outlook. Members of the senior management team will present key developments from the second quarter 2025 results and engage with investors during a Q&A session.

Event Details:

Date: Thursday, August 28, 2025
Time: 10:00 AM – 11:30 AM Eastern Time
Location: Virtual (https://icrinc.zoom.us/webinar/register/WN_EaNErH0vTP683Bj_bz7e_Q)

Investors and analysts interested in attending the meeting are encouraged to join via the link provided above. Additional information, including access details and presentation materials, will be made available on Kyivstar’s Investor Relations website: https://investors.kyivstar.ua.

About Kyivstar

Kyivstar is a Nasdaq-listed company and Ukraine’s leading digital operator, serving nearly 22.4 million mobile customers and over 1.1 million home internet fixed line customers as of June 30, 2025. Kyivstar and its subsidiaries provide services across a wide range of mobile and fixed line technologies, including 4G, big data, cloud solutions, cybersecurity, digital TV, and more. Together with its parent company VEON, Kyivstar intends to invest USD 1 billion in Ukraine during 2023-2027, through social investments in infrastructure and technological development, charitable donations and strategic acquisitions. operating in Ukraine for more than 27 years, Kyivstar is the first Ukrainian investment opportunity in U.S. stock exchanges. For more information, visit https://investors.kyivstar.ua.

About VEON

VEON is a digital operator that provides connectivity and digital services to nearly 160 million customers. Operating across five countries that are home to more than 6% of the world’s population, VEON is transforming lives through technology-driven services that empower individuals and drive economic growth. VEON is listed on Nasdaq. For more information, visit: www.veon.com.


Contact Information

VEON
[email protected]

Kyivstar Group Ltd.
[email protected]
https://investors.kyivstar.ua


 



Genpact Named a Leader in Trust and Safety Services by Everest Group for Fifth Consecutive Year

PR Newswire

2025 PEAK Matrix® recognizes Genpact’s differentiated AI-led solutions to assist with platform safety, compliance, and responsible AI development


NEW YORK
, Aug. 28, 2025 /PRNewswire/ — Genpact (NYSE: G), a global advanced technology services and solutions firm, has been named a Leader in Trust and Safety (T&S) Services by Everest Group in its 2025 PEAK Matrix® Assessment. This marks the fifth consecutive year Genpact has earned this distinction, reinforcing its sustained commitment to trust and safety clients across all major industries. View the ranking here.

“Today, trust and safety is no longer just an operational imperative, it’s a core component of Genpact’s advanced technology solutions portfolio,” said Anil Nanduru, Global Business Leader for High Tech and Manufacturing, and Consumer and Healthcare, Genpact. “By combining strategic guidance with operational execution, we help clients move from reactive responses to proactive risk prevention.”

Everest Group highlighted Genpact’s differentiated solution models across many critical areas, including the following:  

  • AI Development and Safety
     – Embedding resilience to adversarial attacks for responsible AI use and mitigating generative AI risks
  • Platform Safety
     – Enhancing platform integrity through real-time threat detection and policy enforcement
  • Global Tech Compliance
     – Providing regulatory consulting and operational controls to assist with compliance risk management across global markets

“Genpact offers end-to-end trust and safety services to buyers from major industry verticals. It also offers support for T&S benchmarking and guardrail design, transparency reporting, and regulatory risk assessment,” said Abhijnan Dasgupta, Practice Director, Everest Group.

Everest Group evaluated 28 service providers for its 2025 PEAK Matrix®, assessing service scope, innovation, proprietary solutions, and proven impact across client engagements. 

“Genpact continues to invest in trust and safety tools and technology, including investments in AI safety capabilities and Gen AI-based agent assist tools for transformed internal operations,” Dasgupta continued. “It has also established a partnership ecosystem with providers for trust and safety, risk and threat intelligence, red teaming, and analytics to offer technology-based solutions to its clients. These are some of the factors that have contributed to Genpact strengthening its positioning as a Leader in Everest Group’s Trust and Safety Services PEAK Matrix® 2025.”

To learn more about Genpact’s services and solutions for Trust and Safety, click here.

About Genpact
Genpact (NYSE: G) is an advanced technology services and solutions company that delivers lasting value for leading enterprises globally. Through our deep business knowledge, operational excellence, and cutting-edge solutions – we help companies across industries get ahead and stay ahead. Powered by curiosity, courage, and innovation, our teams implement data, technology, and AI to create tomorrow, today. 

Get to know us at genpact.com and on LinkedIn, X, YouTube, and Facebook. 

Everest Group Disclaimer

Licensed extracts taken from Everest Group’s PEAK Matrix® Reports may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group’s PEAK Matrix® reports do not necessarily provide the full context of our research and analysis. All research and analysis conducted by Everest Group’s analysts and included in Everest Group’s PEAK Matrix® reports is independent and no organization has paid a fee to be featured or to influence their ranking. To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix® Reports.  

MEDIA CONTACTS:


Sue Martenson


Genpact Media Relations 

978-905-9582



[email protected]

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/genpact-named-a-leader-in-trust-and-safety-services-by-everest-group-for-fifth-consecutive-year-302540621.html

SOURCE Genpact

Automotive Brand Loyalty Rates Show Mixed Results, according to S&P Global Mobility

PR Newswire


SOUTHFIELD, Mich.
, Aug. 28, 2025 /PRNewswire/ — Industry brand loyalty rates declined slightly in the first half of 2025 following last year’s rebound, according to a new S&P Global Mobility analysis of new vehicle registration data through June.

The industry’s brand loyalty rate through June stood at 51.1%, down 1.4 percentage points (PPs) from the same period in 2024. The decrease marks a reversal from 2024’s year-over-year gain, showing continued volatility in loyalty trends as the market continues to stabilize post-pandemic.

Both mainstream and luxury brands contributed to the decline as more than half of all brands tracked experienced year-over-year loyalty declines of one percentage point or more. Competition from conquests and evolving inventory dynamics reshaped consumer decision-making resulting in a higher rate of defections.

“The loyalty rate shift this year reflects the balance between a steady return-to-market volume and strong competition among brands,” said Vince Palomarez, Associate Director, Loyalty Product Management, S&P Global Mobility. “Households are returning to market, but many are open to cross-shopping in ways we didn’t see during the height of pre-pandemic loyalty.”

Conquest Trends

While industry loyalty slipped, conquest volume rose in the first half of 2025. Conquest activity increased 7.6% among mainstream brands and 6.2% among luxury brands compared with the same period in 2024.

“Conquest opportunities are rebounding, particularly for luxury,” said Tom Libby, Loyalty Solutions and Industry Analysis Associate Director, S&P Global Mobility. “As loyalty softened, brands that executed competitive conquest strategies were able to capture households more effectively.”

Return-to-Market Dynamics

The number of households returning to market rose 4.2% year-over-year in the first half of 2025, representing the third consecutive year of improvement. While this growth provided a larger base of potential loyalists, it also created more opportunities for defections as brands competed aggressively for returning customers.

Additional mid-year highlights for 2025:

  • General Motors led all multi-brand manufacturers with a loyalty rate of 68.1%.
  • Ford topped all brands at 58.9% loyalty.
  • Mini currently leads the industry in loyalty growth, improving its loyalty rate by +4.6 PPs year over year.
  • The Chevrolet Equinox ranked as the model loyalty leader at 42.7%.

S&P Global Mobility experts will share more detail on the mid-year analysis during our next Loyalty webinar on September 4 at 1:00 p.m. ET. Register here to attend. A replay will be available to those who register.

About S&P Global Mobility

At S&P Global Mobility, we provide invaluable insights derived from unmatched automotive data, enabling our customers to anticipate change and make decisions with conviction. Our expertise helps them to optimize their businesses, reach the right consumers, and shape the future of mobility. We open the door to automotive innovation, revealing the buying patterns of today and helping customers plan for the emerging technologies of tomorrow.

S&P Global Mobility is a division of S&P Global (NYSE: SPGI). S&P Global is the world’s foremost provider of credit ratings, benchmarks, analytics and workflow solutions in the global capital, commodity, and automotive markets. With every one of our offerings, we help many of the world’s leading organizations navigate the economic landscape so they can plan for tomorrow, today. For more information, visit www.spglobal.com/mobility.

Media Contact:

[email protected]

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/automotive-brand-loyalty-rates-show-mixed-results-according-to-sp-global-mobility-302541019.html

SOURCE S&P Global Mobility

SERA PROGNOSTICS TO PRESENT AT H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE

PR Newswire


SALT LAKE CITY
, Aug. 28, 2025 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the H.C. Wainwright 27th Annual Global Investment Conference on Friday, September 5, 2025 at 7:00 a.m. ET. Zhenya Lindgardt, President and CEO, will present a company update, highlighting Sera’s latest achievements. The conference, to be held September 8-10, 2025, in New York City, will also include one-on-one investor meetings hosted by the company.

A live webcast of the company’s presentation as well as a webcast replay will be available online from the Investors page of the company’s website at www.sera.com.

About Sera Prognostics, Inc.

Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera’s mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera’s precision medicine PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is headquartered in Salt Lake City, Utah.

About Preterm Birth

Preterm birth is defined as any birth before 37 weeks’ gestation and is the leading cause of illness and death in newborns. The 2024 March of Dimes Report Card shows that, for the last six consecutive years, more than one in ten infants is born prematurely in the United States. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss, and can generate significant costs throughout the lives of affected children. The annual health care costs to manage short- and long-term complications of prematurity in the United States were estimated to be approximately $25 billion for 2016.

About the PreTRM
®
 Test

The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test that provides an early, accurate and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM® Test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM® Test permits physicians to identify, during the weeks 18 through 20 of pregnancy, which women are at increased risk for preterm birth and its complications, enabling more informed, personalized clinical decisions based on each woman’s individual risk. The PreTRM® Test is ordered by a medical professional.

Sera, Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States and/or other countries.

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Company’s participation in the above-mentioned conference(s), as well as the date, time, content and webcast replay availability of the Company’s presentation(s); and the Company’s strategic directives under the caption “About Sera Prognostics, Inc.” These “forward-looking statements” are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: net losses, cash generation, and the potential need to raise more capital; revenues from the PreTRM Test representing substantially all Company revenues to date; the need for broad scientific and market acceptance of the PreTRM Test; a concentrated number of material customers; our ability to introduce new products; potential competition; our proprietary biobank; critical suppliers; estimates of total addressable market opportunity and forecasts of market growth; potential third-party payer coverage and reimbursement; new reimbursement methodologies applicable to the PreTRM Test, including new CPT codes and payment rates for those codes; changes in FDA regulation of laboratory-developed tests; the intellectual property rights protecting our tests and market position; and other factors discussed under the heading “Risk Factors” contained in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our periodic and current reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. 

Contact

Investor Contact

Jennifer Zibuda, Head of Investor Relations
[email protected]
+1 (801) 396-8043

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sera-prognostics-to-present-at-hc-wainwright-27th-annual-global-investment-conference-302539106.html

SOURCE Sera Prognostics, Inc.

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) —


IMUNON


, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market following confirmation from the Nasdaq Hearings Panel. As a result, IMUNON common stock will continue uninterrupted trading on The Nasdaq Capital Market.

“Having regained compliance with Nasdaq’s minimum bid price listing requirement, investors in IMUNON’s stock are assured of efficient liquidity as provided by the exchange. Our ongoing confidence in our listing with the Nasdaq coincides with our recent 15% stock dividend to shareholders of record as of August 7, 2025, reflecting confidence in our clinical pipeline and commitment to rewarding investors,” said Stacy Lindborg, Ph.D., President and CEO of IMUNON. “It also builds on the positive momentum following our unprecedented Phase 2 OVATION 2 trial results for IMNN-001, our DNA-based immunotherapy for the localized treatment of advanced ovarian cancer, a disease that results in 20,000 women newly diagnosed annually in the U.S. alone. We have successfully initiated our Phase 3 OVATION 3 trial in North America, while continuing to advance milestones across our innovative TheraPlas® technology platform.”

About IMUNON

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.

The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.

Forward-Looking Statements

IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the Company’s ability to regain compliance with Nasdaq’s continued listing requirements, the timing of enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, risks and uncertainties related to our ability to regain compliance with Nasdaq’s listing requirements, the potential de-listing of our shares on Nasdaq, risks and uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Contacts:

Media Investors
Jenna Urban Peter Vozzo
CG Life ICR Healthcare
212-253-8881 443-213-0505

[email protected]

[email protected]